Reform Needed at the Food and Drug Administration
One-Size-Fits-All Mandates Don’t Work for Individual Patients
AddThis Social Bookmark Button Email This Print This

Washington, D.C., August 14, 2008—In order to best serve the interests of the nation’s patients and doctors, the structure of the Food and Drug Administration desperately needs to be systematically reformed, according to a new study published by the Competitive Enterprise Institute.

In FDA’s Bad Medicine: How the Dispersed Knowledge Problem Affects Drug Safety Analysis, authors Jerome Arnett, M.D., and Gregory Conko argue that the very structure of the FDA prevents it from doing its job—making sure safe and effective medical treatments reach patients in need.

“Every day, thousands of physicians and patients make myriad choices from available drug options,” write Conko and Arnett. “They take into account differences in effectiveness, side effects, and drug interactions for each individual patient. FDA scientists may know a lot about the drugs they evaluate and their average effects on thousands of users, but they know nothing about the individualized physiology of each patient. On the other hand, intensively trained clinical physicians, who do have knowledge of individual patients, are best able to advise them if a drug is appropriate.”

Because the FDA uses the blunt tool of completely banning drugs that aren’t safe for all patients, there will almost always be those who lie outside the average, and for whom unapproved treatments are not just appropriate, but medically necessary. The government should be encouraging a more personalized approach to treatment, with physicians utilizing multiple sources of information and guidance in tailoring the best possible strategy for each individual patient.

“A market-based approach to drug safety information, combined with technological advances in diagnostic science, will lead to a more vibrant medical marketplace—and better outcomes for patients,” conclude Arnett and Conko.

Additional Resources

* Read the executive summary or the full report (in PDF).

* Watch the CEI video on the problems with the FDA drug approval process.

* Watch “The Simpleton’s Guide to the Food and Drug Administration” on YouTube.

* Read more on CEI’s work on health and safety policy.

CEI is a non-profit, non-partisan public policy group dedicated to the principles of free enterprise and limited government. For more information about CEI, please visit our website at www.cei.org.


AddThis Social Bookmark Button Email This Print This